Nasdaq Markets

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

(RTTNews) - Asian shares crashed on Monday amid selling across the board, with weak China exports data, crashing oil prices and fears surrounding the coronavirus spread weighing on markets.

(RTTNews) - Changyou.com Limited (CYOU) reported fourth-quarter non-GAAP net income from continuing operations per ADS of $1.11, compared to $0.44, a year ago. Non-GAAP net income attributable to Changyou.com was $63 million, compared to $23 million, prior year.

(RTTNews) - Nordex Group (NRDXF.PK) reported Monday that its fiscal 2019 earnings before interest, taxes, depreciation and amortization or EBITDA grew 21.7 percent to 123.8 million euros from previous year's 101.7 million euros.

(RTTNews) - Sogou Inc. (SOGO) reported that its fourth-quarter net income attributable to the company was $35.0 million, a 33% increase from last year.

As American Outdoor Brands (NASDAQ: AOBC) heads toward a split into two companies later this year, the firearms and outdoor gear manufacturer misfired with its fiscal third-quarter earnings report.

The makeover at Disney's (NYSE: DIS) once fledging movie-themed Florida park is complete. Wednesday's debut of Mickey & Minnie's Runaway Railway at Disney's Hollywood Studios completes a two-year revitalization at the park that was dead last in attendance at Disney World w

For a short period, Aurora Cannabis (NYSE: ACB) reigned as the cannabis producer with the largest market cap. After a huge plunge in its stock price over the past year, the company now ranks only in third place. And you could say that its position should be even lower. Constella

In 2017, Netflix (NASDAQ: NFLX) struck a partnership with wireless carrier T-Mobile to include a Netflix subscription in its mobile plans. The streaming leader has since struck numerous partnerships with carriers, video distributors, and internet service providers throughout the

One of the most successful stocks over the past year, 10 years, and 40 years is Apple (NASDAQ: AAPL). Apple is the rare, beloved brand in the technology industry, and it's been equally pleasing to investors. That's especially true of the Tim Cook era, when the company began retu

Good things may come to those who wait, but more often, they come to those who sweat and put in the effort. Home Depot (NYSE: HD) has always been a industry-leading retailer, but in the company's fiscal third quarter, sales came in lower than expected as the return on key invest

You probably have a retirement age in mind, but how likely are you to actually retire then? A recent TD Ameritrade survey crunched the numbers on this and found that the average chosen retirement age among adults 40 to 79 was 67, but the likelihood of actually retiring at that a

Roughly a year and a half ago, Canadian marijuana stocks were expected to take the global lead in making cannabis a mainstream product. But despite having this pole position among developed countries, regulatory and operational issues have caused the Canadian pot industry to fac

Investors gained confidence in Ulta Beauty's (NASDAQ: ULTA) operating outlook after the company announced generally positive earnings results back in early December. Sure, the spa and beauty products retailer is seeing some of its slowest growth in years. Yet Ulta is winning mar

What happened Shares of 3D printing pure plays 3D Systems (NYSE: DDD) and Stratasys (NASDAQ: SSYS) and 3D printing and conventional manufacturing service provider Proto Labs (NYSE: PRLB) fell 15.9%, 11%, and 15.3%, respectively, in February, according to data from S&P Glob

Few stocks have proved to be immune to the coronavirus-fueled market correction that's under way. Marijuana stocks are no exception. Two of the leading cannabis-focused exchange-traded funds (ETFs) have plunged more than 30% from their highs set earlier this year.

I've been writing about and investing in the energy industry for nearly a decade. It hasn't been a smooth ride. A combination of commodity price volatility and poor capital allocation decisions have caused the sector to generate poor investment returns in recent years. That ha

Managing money successfully can be challenging, and no one is perfect at it. In fact, money mistakes are very common; everyone makes them from time to time. The key is, when something goes wrong, you need to respond quickly and correctly so you can minimize the damage.

The coronavirus’ grip on the market continues. Since the beginning of February, the S&P 500 has shed 8.5% of its value, a reflection of the effect the outbreak is having on the global economy. Amidst the bloodbath, one specific group of stocks is holding up. These are the drug companies those infected, the public at large and investors are hoping can halt the virus from spreading any further. Gilead Sciences (GILD) is among those leading the search for a treatment and is currently being rewarded by the market. In contrast to the broader market, GILD stock is up 23% year-to-date.

Remdesivir, one of the company’s existing drugs which was previously tested as a possible treatment for Ebola, is being tested as a potential treatment for COVID-19.

Gilead has initiated two Phase III studies in China, one in severe patients and one in patients with moderate symptoms. The trials will have short endpoints (14 days), with the possibility of data readouts in April.

In addition to the coronavirus developments, Gilead also recently announced it will acquire immuno-oncology specialist Forty Seven, in a deal worth $4.9 billion.

While Jefferies’ Michael Yee remains positive on Gilead’s prospects, the 4-star analyst tempers expectations of the drug’s financial impact. “We applaud the efforts - but reiterate while this is fundamentally positive, the financial implications are modest (pricing, one-time use, no tail). Also, in our discussions, while GILD is hopeful on the efficacy, they caution CV should not be a key driver to valuation, since it is mostly humanitarian and unlikely to drive any material benefits. In our math, even at a $1,000-5,000 price x 500,000 estimate points, this is $500 million-$2 billion-plus but GILD has been known to give away aid to regions at cost,” said Yee

Yee reiterated a Buy on Gilead, along with a price target of $76. Gilead’s recent surge means the figure currently implies possible downside of 5.26%. (To watch Yee’s track record, click here)

Maxim Group’s Jason McCarthy is also skeptical of the drug’s ability to drive profit.

The analyst noted, “The coronavirus threat is real, and it should be a concern to the public-no question. However, from an investing perspective, we view remdesivir as a relatively modest opportunity at best for Gilead, and not a growth driver. That said, we are not at all minimizing Gilead's efforts to rapidly advance remdesivir to see if they have a drug for coronavirus that could save lives. Actually, the company's efforts are impressive to say the least. We are looking at it purely through the lens of the value proposition and the growth prospects of the company; fundamentals vs. hype.”

Accordingly, McCarthy remains on the fence and maintains his Hold rating. The analyst currently has no price target. (To watch McCarthy’s track record, click here)

The Street’s take on the virus fighter is currently split almost evenly down the middle. 9 Buys, 9 Holds and 1 Sell add up to a Moderate Buy consensus rating. The average price target is $75.94 and implies that the analysts see the stock dropping 5.34% from current levels. (See Gilead stock-price forecast on TipRanks)

To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.